254 related articles for article (PubMed ID: 25591817)
1. Establishing implantation uncertainties for focal brachytherapy with I-125 seeds for the treatment of localized prostate cancer.
Polders DL; Steggerda M; van Herk M; Nichol K; Witteveen T; Moonen L; Nijkamp J; van der Heide UA
Acta Oncol; 2015 Jun; 54(6):839-46. PubMed ID: 25591817
[TBL] [Abstract][Full Text] [Related]
2. Magnetic resonance imaging-defined treatment margins in iodine-125 prostate brachytherapy.
Crook J; Patil N; Ma C; McLean M; Borg J
Int J Radiat Oncol Biol Phys; 2010 Jul; 77(4):1079-84. PubMed ID: 19879700
[TBL] [Abstract][Full Text] [Related]
3. Treatment margins for prostate brachytherapy.
Han B; Wallner K; Aggarwal S; Armstrong J; Sutlief S
Semin Urol Oncol; 2000 May; 18(2):137-41. PubMed ID: 10875455
[TBL] [Abstract][Full Text] [Related]
4. Prostate seed implantation using 3D-computer assisted intraoperative planning vs. a standard look-up nomogram: Improved target conformality with reduction in urethral and rectal wall dose.
Raben A; Chen H; Grebler A; Geltzeiler J; Geltzeiler M; Keselman I; Litvin S; Sim S; Hanlon A; Yang J
Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1631-8. PubMed ID: 15590195
[TBL] [Abstract][Full Text] [Related]
5. The effect of catheter displacement and anatomical variations on the dose distribution in MRI-guided focal HDR brachytherapy for prostate cancer.
Maenhout M; van der Voort van Zyp JRN; Borot de Battisti M; Peters M; van Vulpen M; van den Bosch M; Moerland MA
Brachytherapy; 2018; 17(1):68-77. PubMed ID: 28579419
[TBL] [Abstract][Full Text] [Related]
6. New approach of ultra-focal brachytherapy for low- and intermediate-risk prostate cancer with custom-linked I-125 seeds: A feasibility study of optimal dose coverage.
Brun T; Bachaud JM; Graff-Cailleaud P; Malavaud B; Portalez D; Popotte C; Aziza R; Lusque A; Filleron T; Ken S
Brachytherapy; 2018; 17(3):544-555. PubMed ID: 29525514
[TBL] [Abstract][Full Text] [Related]
7. A comparative study of seed localization and dose calculation on pre- and post-implantation ultrasound and CT images for low-dose-rate prostate brachytherapy.
Ali I; Algan O; Thompson S; Sindhwani P; Herman T; Cheng CY; Ahmad S
Phys Med Biol; 2009 Sep; 54(18):5595-611. PubMed ID: 19717887
[TBL] [Abstract][Full Text] [Related]
8. Dosimetry modeling for focal high-dose-rate prostate brachytherapy.
Mason J; Al-Qaisieh B; Bownes P; Thwaites D; Henry A
Brachytherapy; 2014; 13(6):611-7. PubMed ID: 25085456
[TBL] [Abstract][Full Text] [Related]
9. The effect of the radial function on I-125 seeds used for permanent prostate implantation.
Pickett B; Pouliot J
Med Dosim; 2004; 29(3):204-9. PubMed ID: 15324917
[TBL] [Abstract][Full Text] [Related]
10. Improved tumour control probability with MRI-based prostate brachytherapy treatment planning.
Dinkla AM; Pieters BR; Koedooder K; van Wieringen N; van der Laarse R; van der Grient JN; Rasch CR; Koning CC; Bel A
Acta Oncol; 2013 Apr; 52(3):658-65. PubMed ID: 23282111
[TBL] [Abstract][Full Text] [Related]
11. Correlation between pre- and postimplant dosimetry for iodine-125 seed implants for localized prostate cancer.
Al-Qaisieh B; Witteveen T; Carey B; Henry A; Bottomley D; Smith J; Franks K; Bownes P
Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):626-30. PubMed ID: 19540077
[TBL] [Abstract][Full Text] [Related]
12. The dependence of prostate postimplant dosimetric quality on CT volume determination.
Merrick GS; Butler WM; Dorsey AT; Lief JH
Int J Radiat Oncol Biol Phys; 1999 Jul; 44(5):1111-7. PubMed ID: 10421545
[TBL] [Abstract][Full Text] [Related]
13. Focal prostate brachytherapy with (103)Pd seeds.
Butler WM; Merrick GS
Phys Med; 2016 Mar; 32(3):459-64. PubMed ID: 27053451
[TBL] [Abstract][Full Text] [Related]
14. Brachytherapy in patients with small prostate glands.
Loblaw DA; Wallner K; Dibiase S; Russell K; Blasko J; Ellis W
Tech Urol; 2000 Jun; 6(2):64-9. PubMed ID: 10798802
[TBL] [Abstract][Full Text] [Related]
15. High-dose-rate prostate brachytherapy consistently results in high quality dosimetry.
White EC; Kamrava MR; Demarco J; Park SJ; Wang PC; Kayode O; Steinberg ML; Demanes DJ
Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):543-8. PubMed ID: 22652111
[TBL] [Abstract][Full Text] [Related]
16. Moving toward focal therapy in prostate cancer: dual-isotope permanent seed implants as a possible solution.
Todor DA; Barani IJ; Lin PS; Anscher MS
Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):297-304. PubMed ID: 21536392
[TBL] [Abstract][Full Text] [Related]
17. The radiation doses to erectile tissues defined with magnetic resonance imaging after intensity-modulated radiation therapy or iodine-125 brachytherapy.
Buyyounouski MK; Horwitz EM; Uzzo RG; Price RA; McNeeley SW; Azizi D; Hanlon AL; Milestone BN; Pollack A
Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1383-91. PubMed ID: 15275723
[TBL] [Abstract][Full Text] [Related]
18. Influence of dose on risk of acute urinary retention after iodine-125 prostate brachytherapy.
Roeloffzen EM; Battermann JJ; van Deursen MJ; Monninkhof EM; Visscher MI; Moerland MA; van Vulpen M
Int J Radiat Oncol Biol Phys; 2011 Jul; 80(4):1072-9. PubMed ID: 20615621
[TBL] [Abstract][Full Text] [Related]
19. Modification of prostate implants based on postimplant treatment margin assessment.
Mueller A; Wallner K; Merrick G; Courveau J; Sutlief S; Butler W; Gong L; Cho P
Med Phys; 2002 Dec; 29(12):2782-7. PubMed ID: 12512711
[TBL] [Abstract][Full Text] [Related]
20. Inverse automated treatment planning with and without individual optimization in interstitial permanent prostate brachytherapy with high- and low-activity 125I.
Pinkawa M; Maurer U; Mulhern A; Gagel B; Block T; Borchers H; Grieger J; Henkel T; Eble M
Strahlenther Onkol; 2003 Jun; 179(6):417-22. PubMed ID: 12789469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
